On average it takes more than 10 years to develop a new medical treatment. The costs can amount to up to more than 1 billion dollars, and it is essential to be able to recoup these investments.
Patenting facilitates early publication of new inventions
and in return gives the inventor an exclusive right to use the
invention commercially for a limited period of time, usually 20
years. Without patents many life-saving medicines would never have
been made available for those who need them.
In many developing countries it is a difficult and complex challenge to ensure that sufficient treatment is made available for all. It is our goal to develop better medical solutions that can radically improve the lives of people with diabetes, haemophilia and other conditions.
We therefore depend on efficient protection of our intellectual property rights. We aim to ensure that our innovations contribute to better health for people across the world.
We are the largest provider of human insulin worldwide. Human insulin is an essential drug on the WHO Model List of Essential Medicines and has been off patent for many years. This means human insulin is in the public domain and can be manufactured in any part of the world without the need of a license to any patents.
We make human insulin available to the world's least developed countries - LDCs (as defined by the United Nations) through our Access to Insulin Commitment where human insulin is offered at a maximum of 20% of the realised price in Europe, the US, Canada and Japan. In many other low- and middle-income countries, we sell human insulin at equally low prices through large government tenders reaching millions of people with diabetes. As a consequence, we do not view non-exclusive voluntary licensing as the appropriate tool to ensure access to essential diabetes medicines like human insulin.
We are committed to advancing the responsible use of intellectual property rights for the benefit of human health.